Wenjing Jiang
Anhui Provincial Cancer Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Wenjing Jiang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:51 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06437353 · Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian CancerAnhui Provincial Cancer Hospital · recruiting · Ovarian Cancer · study director
- Ph2NCT05652283 · Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian CancerBai-Rong Xia · active not recruiting · Ovarian Cancer · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:51 UTC. The ranking covers the 200 most relevant of 496 PubMed records, and a shared surname and initials can bring in a namesake. All 496 on PubMed
- A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.Neurology · 2012225 citationsRCR 8.6
- Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients.Immunol Invest · 2003191 citationsRCR 5.2
- Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study.Int J Cancer · 2022165 citationsRCR 10.0
- 157 citationsRCR 7.5
- Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.J Natl Cancer Inst · 2007149 citationsRCR 2.9
- Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.Clin Cancer Res · 2020135 citationsRCR 4.9
- Fractional Flow Reserve or Intravascular Ultrasonography to Guide PCI.N Engl J Med · 2022131 citationsRCR 10.6
- Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values.Am J Transplant · 201997 citationsRCR 6.5
- 96 citationsRCR 5.7
- A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma.Int J Cancer · 201491 citationsRCR 2.9